Health Condition 1: null- Hypogonadism
Conditions
Interventions
Intervention1: testosterone undecanoate
(Injection Cernos): Patients will be given Inj. Testosterone undecanoate 1000 mg (4ml) at baseline , 6 weeks followed by then every 12 weeks and pati
Sponsors
Research Cell
Eligibility
Inclusion criteria
Inclusion criteria: Patients with hypergonadotropic hypogonadism and isolated hypogonadotropic hypogonadism
Exclusion criteria
Exclusion criteria: 1. Patients who have any chronic illness, hypothyroidism or hyperthyroidism , liver disease or treatment with drugs knowing to interfere with glucose homeostasis or fat metabolism (e.g. glucocorticoids). 2. Patients with cortisol deficiency or secondary hypothyroidism or GH deficiency in patients with hypogonadotropic hypogonadism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Prevalence of glucose intolerance, metabolic syndrome and beta-cell function/insulin resistance in patients with hypogonadism and age matched healthy controls. 2. Change in glucose intolerance, metabolic syndrome and beta-cell function /insulin resistance in patients with hypogonadism treated with testosterone replacement over a period of 9 months.Timepoint: 1. Prevalence of glucose intolerance, metabolic syndrome and beta-cell function/insulin resistance in patients with hypogonadism and age matched healthy controls at diagnosis. 2. Change in glucose intolerance, metabolic syndrome and beta-cell function /insulin resistance in patients with hypogonadism treated with testosterone replacement over a period of 9 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| NoneTimepoint: none | — |
Countries
India
Contacts
Public ContactDr Kora Chandra Obul Reddy
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Outcome results
None listed